Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

@article{Marder2003AripiprazoleIT,
  title={Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.},
  author={Stephen R Marder and Robert D. McQuade and Elyse G Stock and Stephen Kaplita and Ronald Marcus and Allan Z. Safferman and Anutosh R. Saha and Mirza Kazim Ali and Taro Iwamoto},
  journal={Schizophrenia research},
  year={2003},
  volume={61 2-3},
  pages={123-36}
}
Aripiprazole is a novel antipsychotic with a unique mechanism of action. Presented here is a pooled analysis of safety and tolerability data from all completed short-term, placebo-controlled trials in schizophrenia from the aripiprazole clinical development program. Data were analyzed from five 4- to 6-week double-blind multicenter studies of patients hospitalized with acute relapse of schizophrenia or schizoaffective disorder randomized to aripiprazole (n=932), placebo (n=416), or haloperidol… CONTINUE READING